Objective and design: The use of proton pump inhibitors in acid-related diseases such as peptic ulcer or erosive reflux oesophagitis is well established. The aim of the current nationwide, multicentre ...
Please provide your email address to receive an email when new articles are posted on . A 500 mg intramuscular injection of sotrovimab was noninferior to an IV infusion of the investigational ...
Please provide your email address to receive an email when new articles are posted on . More patients in the ED with hemoptysis saw an end to the condition with nebulized vs. IV tranexamic acid.
The benefit of reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) as salvage treatment for relapsing multiple myeloma (MM) Bortezomib (Bz) is a novel proteasome ...
RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients. Background: To date convincing clinical success with oncolytic ...
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today ...
CHICAGO — Administering the bispecific antibody amivantamab (Rybrevant) subcutaneously rather than intravenously in combination with lazertinib (Leclaza) not only reduces administration times but also ...
The phase 3 IRAKLIA trial showed isatuximab's OBDS matches IV efficacy and pharmacokinetics, with fewer injection-site reactions. Subcutaneous isatuximab demonstrated a 71.1% objective response rate, ...
The U.S. Food and Drug Administration (FDA) has approved the first medication delivered intravenously to reduce both episodic and chronic migraine. The FDA gave the go-ahead based on research showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback